QSAR studies of quinidine inhibition of CYP2D6

被引：0
|
作者：
Hutzler, JM [1 ]
Wienkers, LC [1 ]
机构：
[1] Pharmacia Corp, Global Drug Metab, Kalamazoo, MI 49007 USA
来源：
DRUG METABOLISM REVIEWS | 2002年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
343
引用
收藏
页码：172 / 172
页数：1
相关论文
共 50 条
  • [11] Inhibition of CYP2D6 activity by bupropion
    Kotlyar, M
    Brauer, LH
    Tracy, TS
    Hatsukami, DK
    Harris, J
    Bronars, CA
    Adson, DE
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (03) : 226 - 229
  • [12] QSAR Studies of CYP2D6 Inhibitor Aryloxypropanolamines Using 2D and 3D Descriptors
    Roy, Partha Pratim
    Roy, Kunal
    CHEMICAL BIOLOGY & DRUG DESIGN, 2009, 73 (04) : 442 - 455
  • [13] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [14] Fuzzy pharmacophore triplets: New descriptors for the construction of QSAR models and application to Cyp2D6 inhibition
    Barbosa, Frederique
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232 : 126 - 126
  • [15] Inhibition of CYP2D6 by antipsychotic drugs.
    Shin, JG
    Soukhova, N
    Desta, Z
    Flockhart, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 188 - 188
  • [16] CYP2D6 inhibition in patients treated with sertraline
    Sproule, BA
    Otton, SV
    Cheung, SW
    Zhong, XH
    Romach, MK
    Sellers, EM
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (02) : 102 - 106
  • [17] Dynamics and persistence of CYP2D6 inhibition by paroxetine
    Jurica, J.
    Zourkova, A.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (04) : 294 - 300
  • [18] Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine
    Bertelsen, KM
    Venkatakrishnan, K
    Von Moltke, LL
    Obach, RS
    Greenblatt, DJ
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) : 289 - 293
  • [19] Exposure to oral oxycodone is increased by simultaneous inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone
    Gronlund, J.
    Hagelberg, N.
    Saari, T.
    Neuvonen, P.
    Olkkola, K.
    EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2010, 27 (01) : 144 - 144
  • [20] Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone
    Gronlund, Juha
    Saari, Teijo I.
    Hagelberg, Nora M.
    Neuvonen, Pertti J.
    Olkkola, Klaus T.
    Laine, Kari
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (01) : 78 - 87
12345